✦ LIBER ✦

Absence of clinically relevant drug-drug interaction between odanacatib and digoxin after concomitant administration

✍ Scribed by Stoch, S. Aubrey; Witter, Rose; Hreniuk, David; Liu, Chengcheng; Zajic, Stefan; Mehta, Anish; Brandquist, Christine; Dempsey, Cynthia; DeGroot, Bruce; Stypinski, Daria; Denker, Andrew; Wagner, John A.

Book ID: 121402942
Publisher: Dustri Verlag
Year: 2013
Tongue: English
Weight: 370 KB
Volume: 51
Category: Article
ISSN: 0946-1965
DOI: 10.5414/CP201864

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Lack of Clinically Relevant Drug–Drug In

Lack of Clinically Relevant Drug–Drug Interaction Between Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, and Verapamil, Ramipril, or Digoxin in Healthy Volunteers

✍ Macha, Sreeraj; Sennewald, Regina; Rose, Peter; Schoene, Katja; Pinnetti, Sabine 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 520 KB

Absence of clinically relevant drug inte

Absence of clinically relevant drug interactions following simultaneous administration of didanosine-encapsulated, enteric-coated bead formulation with either itraconazole or fluconazole

✍ B. Damle; H. Hess; S. Kaul; C. Knupp 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB

A pharmacokinetic and pharmacodynamic st

A pharmacokinetic and pharmacodynamic study of drug–drug interaction between ginsenoside Rg1, ginsenoside Rb1 and schizandrin after intravenous administration to rats

✍ Zhan, Shuyu; Guo, Wenjing; Shao, Qing; Fan, Xiaohui; Li, Zheng; Cheng, Yiyu 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 473 KB

Pharmacokinetics of enrofloxacin and flu

Pharmacokinetics of enrofloxacin and flunixin meglumine and interactions between both drugs after intravenous co-administration in healthy and endotoxaemic rabbits

✍ Muammer Elmas; Enver Yazar; Kamil Uney; Ayşe Er (Karabacak); Bünyamin Traş 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 154 KB

Drug interactions between the proteasome

Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF), and TNF-related apoptosis-inducing ligand (TRAIL) in prostate cancer: An J, Sun Y-P, Adams J, Fisher M, Belldegrun A, Rettig MB, Veterans Administration Greater Los Angeles Healthcare System, Los Angeles, CA [J An, Y-PS, MF, MBR]; Millennium Pharmaceuticals, Inc., Cambridge, MA [J Adams]; and University of California at Los Angeles School of Medicine, Los Angeles, CA [AB, MBR]. Clinical Cancer Research 2003;9:4537–4545

✍ Gurkamal Chatta 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 18 KB